Recent Updates
Recently added Catalysts
MASS Positive Sentiment

908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue

Tuesday, November 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: 908 Devices Inc. reported strong financial results for Q3 2026, with revenue increasing by 35% year-over-year to $19 million. The growth was primarily driven by their FTIR portfolio, and device shipments reached a record high. CEO Kevin J. Knopp highlighted the company's positive trajectory.

Market Sentiment Analysis

POSITIVE FACTORS

  • Revenue grew 35% year-over-year to $19 million.
  • Device shipments reached a new company record.
  • Strong performance driven by the FTIR portfolio.

Full Press Release Details

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety, and defense tech applications, today reported financial results for the quarter ended September 30, 2026. "We had a strong third quarter, driven by our FTIR portfolio, with revenue growing 35% year-over-year to $19 million and device shipments reaching a new company record,” said Kevin J. Knopp, CEO and Co-founde

Frequently Asked Questions

What was 908 Devices' Q3 2026 revenue?

The company reported $19 million in revenue for the third quarter of 2026.

How did Q3 2026 revenue grow year-over-year?

Revenue grew by 35% compared to the same period in the previous year.

What product portfolio drove the revenue growth?

Growth was primarily driven by the company's FTIR portfolio of handheld tools.

Did 908 Devices set any new records?

Yes, device shipments reached a new company record during the quarter.

ShareAdd on Google
Tags: MASS 908 Devices Q3 2026 revenue growth FTIR portfolio
Last updated: Nov 10, 2026

Biotech snapshot

Cash runway
$102M liquidity · $0M/mo burn
Low dilution risk